WO1996016070A1 - Substance mk7634, procede de production de ladite substance et anthelmintique la contenant - Google Patents
Substance mk7634, procede de production de ladite substance et anthelmintique la contenant Download PDFInfo
- Publication number
- WO1996016070A1 WO1996016070A1 PCT/JP1995/002387 JP9502387W WO9616070A1 WO 1996016070 A1 WO1996016070 A1 WO 1996016070A1 JP 9502387 W JP9502387 W JP 9502387W WO 9616070 A1 WO9616070 A1 WO 9616070A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substance
- water
- culture
- medicament
- active ingredient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/145—Fungal isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/02—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using fungi
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
Definitions
- the present invention relates to a substance having an anthelmintic activity, a method for producing the substance, and a use thereof as an anthelmintic agent.
- a disease called parasite disease is caused by the infestation of a host with parasites, and has serious damage to human and animal health and agriculture.
- anthelmintic active substances derived from microorganisms, destomycin, hygromycin, avermectin and the like have been reported, but the number is extremely small. Therefore, the emergence of new anthelmintic active substances is constantly being sought.
- the present inventors seek to solve this problem by providing a novel compound having an anthelmintic effect, establishing an advantageous production method thereof, and providing an anthelmintic agent containing the active substance. .
- DISCLOSURE OF THE INVENTION The present inventors have continued to search for substances having anthelmintic activity in order to meet the above-mentioned expectations, and found that substances having anthelmintic activity are produced in cultures of strains belonging to incomplete bacteria.
- the present invention was completed by isolating the active ingredient and determining its physicochemical properties.
- the present invention relates to a basic water-soluble substance having the following physicochemical properties (hereinafter referred to as ⁇ ⁇ ⁇ ⁇ ⁇ substance) and a method for producing the same, and ⁇ ⁇ 3 ⁇ substance as an active ingredient And particularly to anthelmintic agents.
- ⁇ ⁇ ⁇ ⁇ ⁇ substance a basic water-soluble substance having the following physicochemical properties
- ⁇ ⁇ 3 ⁇ substance as an active ingredient
- anthelmintic agents e.g., anthelmintic agents.
- Solubility soluble in water, insoluble in ether, black form and ethyl acetate.
- FIG. 1 is a drawing showing a UV spectrum of an MK 7634 substance in an aqueous solution.
- FIG. 2 is a drawing showing an IR spectrum of the MK 7634 substance by the KBr method.
- the MK 7634 substance of the present invention can be obtained, for example, by culturing a microorganism capable of producing the MK 7634 substance against incomplete bacteria and collecting the microorganism from the culture.
- the microorganism is not particularly limited as long as it satisfies the above-mentioned conditions, but preferably includes a microorganism producing the substance belonging to Curvularia (Curvia1aria).
- the present inventors isolated the deceased plant from the dead plant (Cu rvul laria pa lesscens) D 2479 (hereinafter may be abbreviated as “the strain” or “D 2479”), More preferable production bacteria can be mentioned.
- the colony was grown on a potato-dextrose agar [PDA: Potato leachate powder 4.0 g, glucose 20.0 g, and agar 15.Og (manufactured by Nissui Pharmaceutical Co., Ltd.) in 1 L of water (pH 6. 0 ⁇ 0.1): Nissui Pharmaceutical Co., Ltd. Product Handbook I. p92], 27, above, vigorous after 2 weeks of cultivation, colony shape fluffy, light brown-grey at first, dark brown later .
- PDA Potato leachate powder 4.0 g, glucose 20.0 g, and agar 15.Og (manufactured by Nissui Pharmaceutical Co., Ltd.) in 1 L of water (pH 6. 0 ⁇ 0.1): Nissui Pharmaceutical Co., Ltd. Product Handbook I. p92], 27, above, vigorous after 2 weeks of cultivation, colony shape fluffy, light brown-grey at first, dark brown later .
- the basal hypha is branched and has a large number of partition walls, 3.0-16 / m in width, and is light brown to dark brown.
- Chlamydospores are not formed.
- Conidiophores occur solitarily, apical or lateral on vegetative mycelium, usually unbranched But sometimes branched, erect or curved, often zigzag above, light brown to dark reddish brown, with several partitions, 70-450 m long, 3.8-5.0 m wide , Thin at the base, enormous towards the tip.
- Conidium spindle-shape club-shaped, 3 septum, 3rd cell from bottom huge, 3rd cell curved or uncurved, conidial cells are all uniform Light brown, smooth, 17.8-31.2 x 5.3: 12.0 um, lacking protruding navel (hi 1 um) at conidia base.
- Malt agar medium [MA (Malt extract Agar): a medium containing malt extract 20.0 g, peptone 1.0 g dextrose 20.0 g, and agar agar 20.0 g in 1 L of water (pH uncorrected): Fungi Guidebook (bottom) p1281, Utagawa Shunichi and Tsubaki Keisuke et al. (Kodansha)], 27, 2 weeks of cultivation, colonies grow vigorously, colonies appear fluffy to velvety, light brownish gray at first, then grayish black .
- MA Malt agar medium
- the basal hypha is branched, has a large number of septa, reaches 14.7 m in width, and is pale brown to reddish brown.
- Chlamydospores are not formed.
- Aerial hyphae are abundantly formed.
- Conidia formation is abundant, and conidiophores and conidia anamorphic properties are similar to those on PDA media.
- the basal hypha is branched, has a large number of septa, and has a width of 2.2 to 10 / m and a pale to pale brown color.
- Chlamydospores are not formed.
- Aerial hyphae are abundantly formed. Conidia formation is particularly abundant at the periphery of the colony, and the conidiophores and conidia anamorphic properties are similar to those on PDA medium.
- This strain (D 2479) has 1) a polo-type conidium-forming mode, 2) a conidiophore that is straight or curved, often zigzag, and forms a conidium in an apical manner.
- 3-Polo of incomplete mycoplasma-incomplete filamentous fungi due to the features of having a septum, always having a huge number of intermediate cells, and a mixture of conidia curved in a round shape It belongs to Culbularia II (Cur Vu 1 aria), a type conidia forming group. It is distinguished from its closely related genus D rechslera in the nature of conidia (having a true septum, three to four septum, and a large number of intermediate cells). .
- Hyphomycetes, MB Ellis (1971) these 40 species differ in host plant, conidia shape (with or without hi 1 um at the base of conidia, number of septa, size of conidia, shape, The presence or absence of curvature, etc.).
- the species search table described in Dematiaceous Hyphomycetes,. B. Ellis, ⁇ ⁇ 452-459 (1971) the species level of this strain (D2479) was searched. C. pallescens). Therefore, this strain (D2479) is Culbularia no. Resens (C. pal 1 escens). Closely related species are Culbularia lunata (C. 1 unata) and Culbularia leonensis (C. 1 eonensis).
- Culbularia nogense (C. pal 1 escens) is characterized by the characteristics shown in Table 1 below. Can be distinguished from Features of conidia D 2 4 7 9 C. pallescens C. leonensis C. lunata Number of bulkheads 3 3
- This strain is liable to change its properties as seen in other molds.
- any strain of this strain, or a mutant strain (naturally occurring or inducible) derived therefrom, a transzygote or a recombinant gene, that produces the MK7634 substance Departure is liable to change its properties as seen in other molds.
- Cultivation method of MK7634 substance-producing bacteria Cultivate MK7634 substance-producing bacteria belonging to the chromosome chromosome ⁇ defective filamentous fungus in a medium containing nutrients that can be used by ordinary microorganisms .
- the nutrient source known nutrients conventionally used for culturing fungi can be used.
- a carbon source rice, glucose, starch syrup, dextrin, starch, molasses, flora, vegetable oil and the like can be used.
- soybean flour, wheat germ, corn steep liquor, cottonseed kashiwa, meat extract, leptone, yeast extract, ammonium sulfate, sodium nitrate, urea and the like can be used. If necessary, it is also effective to add sodium, potassium, calcium, magnesium, cobalt, chlorine, phosphoric acid, sulfuric acid and other inorganic salts capable of forming ions.
- organic and inorganic substances that support the growth of the fungus and promote the production of the MK7634 substance can be added as appropriate.
- Suitable culture methods are aerobic culture methods, especially solid culture and submerged culture. ing.
- the temperature suitable for culturing is 15 to 35, but more preferably 20 to 30.
- Production of the MK7634 substance varies depending on the culture medium and culture conditions, but the highest accumulation usually occurs in 2 to 14 days in solid culture, shaking culture, and tank culture. Stop the culture when the accumulated amount of MK7634 in the culture reaches the maximum, and simply purify the target substance from the culture solution.
- the MK7634 substance obtained according to the present invention can be obtained from a culture of an MK7634 substance-producing bacterium by a usual separation method utilizing its properties, for example, a solvent extraction method, an ion exchange resin method, an adsorption or distribution column chromatography method, and gel filtration. , Dialysis, precipitation and the like can be used alone or in an appropriate combination for extraction and purification.
- MK7634 substance is extracted from cultured cells with acetone-water, methanol-water, etc. The aqueous layer from which acetone or methanol contained in this extract is distilled off is washed successively with ethyl acetate, n-butanol and the like.
- the sample obtained by freeze-drying is subjected to a molecular sieving resin (manufactured by Pharmacia, trade name: Sephadex G-10), followed by a molecular sieving resin (manufactured by Tosoh Corporation; MK7634 substance can be purified by performing gel filtration chromatography such as TOYOPEARL ⁇ HW-40 S).
- a molecular sieving resin manufactured by Pharmacia, trade name: Sephadex G-10
- MK7634 substance can be purified by performing gel filtration chromatography such as TOYOPEARL ⁇ HW-40 S).
- the MK7634 substance can be used as an active ingredient of a medicine, particularly as an active ingredient of an anthelmintic.
- Animals to which the MK7634 substance is to be applied as an anthelmintic include humans, pigs, cows, horses, rabbits, sheep, goats, chickens, ducks, turkeys, 20-day rats, large black rats, guinea pigs, monkeys, dogs, cats And domestic animals such as small birds, poultry, experimental animals, and pets.
- the parasites of these animals include, for example, cattle, sheep torsion stomach, oestertag stomach, hairy worm, Cooper nematode, intestinal nodule, fecal nematode, double-mouth fluke, benedin tapeworm, lung Insects, fluke, etc., roundworms of pigs, whipworms, intestinal tuberculosis, etc., roundworms of dogs, hookworms, whipworms, wireworms, etc., roundworms of cats, mansonous tapeworms, roundworms of chickens, hair There are mite worms and caecum worms.
- human roundworms, pinworms, and hookworms Zubinii hookworm, Sylon hookworm, American hookworms), oriental hairy nematodes, ⁇ nematodes, and whipworms are known.
- the MK 7634 substance can be used for treatment and prevention of various diseases, particularly for treatment and prevention of parasitic infections.
- the method of administration for treatment is oral or parenteral.
- a liquid formulation is forcibly administered using a gastric catheter or other device, mixed with normal feed or drinking water, or administered orally.
- a suitable dosage form for example, tablet, capsule, pellet, bolus, powder or soft capsule.
- a water-insoluble formulation such as peanut oil or soybean oil, or a water-soluble formulation such as glycerol or polyethylene glycol is injected into the skin, subcutaneously, intramuscularly, intravenously, intraperitoneally, etc. Administer.
- the method of administration for the prevention of parasites is generally mixed with a commonly used feed or the like and administered orally or by injection. There are no restrictions on the duration of treatment, but for example, about 2 months for normal chickens and 5 months for pigs are often sufficient.
- the dose of the MK 7634 substance varies depending on the target animal, the type of parasite, or the method of administration.
- the dose should be 3 mg / kg or more, preferably 6 mg / Zkg or more.
- the dose for prophylaxis is continuously administered at a concentration of 1 ppm or more, preferably 5 to 10 ppm in the feed.
- the MK7634 substance when dissolved or suspended in a liquid carrier, it can be administered parenterally by injection into animals subcutaneously or intramuscularly.
- a liquid carrier for parenteral administration, water-insoluble formulations using vegetable oils such as peanut oil and soybean oil are used, and aqueous parenteral formulations using water-soluble excipients such as glycerol and polyethylene glycol are also used. Is done. These formulations generally contain 0.1 to 10% by weight of the MK7634 substance.
- the dose for parenteral administration is 0.5 mg / kg or more per day, preferably in the range of 1-2 O mg Z kg.
- Example 1 starch syrup 2.0%, soy flour 1.0%, soybean oil 0.15%, sun grains (manufactured by Suntory Ltd.) 0.25% cottonseed kashiwa 0.5%, FeS 04 ⁇ 7H 2 0 0.0005%, NiC 12 ⁇ 6 medium containing H 2 0 0. 00005%, C o C 12 ⁇ 6 H 2 0 0.00005%, and a C a C Oa 0.1%
- a resin for molecular sieving (Sephadex G-10, manufactured by Pharmacia) was packed in a column with 47 Om1, and 5.5 g of the active fraction was selected from the following: O g was dissolved in 2 Om 1 of purified water, and column chromatography was performed using purified water under the condition of pH 7.9, fractionated by 2 ml each, and fractions N 0.19 to ⁇ 30 were collected. 145 mg of the active fraction was obtained.
- the physicochemical properties of the MK 7634 substance are as described above.
- the molecular weight and chemical composition were confirmed by measuring a high-resolution mass spectrum of a monodansyl compound obtained by dansylating the substance.
- the chemical shifts and binding constants of ' ⁇ -NMR (Fig. 3) in a mixed solution of the monodansyl form of MK7634 substance in heavy water and heavy methanol (weight mixing ratio 4: 1), and 13
- the chemical shift values of C-NMR ( Figure 4) are shown below.
- Example 2 Roundworm artificially infected chickens confirmed to have been infected with roundworm by egg inspection were divided into four birds per group, each at 4 o'clock, and a total of five birds including the non-medicated group were subjected to the test.
- a dose accurately calculated from the body weight of each chicken was filled in a gelatin capsule and orally administered 311 times using a gastric probe. After the administration, the number of excreted insects was counted every day for each chicken, and 7 days later, each chicken was dissected without being dissected, and the number of remaining insects in the intestinal tract was counted to calculate the extermination rate.
- Exclusion rate-Number of excreted bodies for 7 days / 96 (Number of excreted bodies for 7 days + Number of residual bodies) x 100
- the body weight immediately before administration and the body weight after 7 days were measured for each chicken, was calculated.
- Growth rate-(body weight 7 days after administration-body weight at administration) Body weight at administration X 100 The above test results are as shown in Table 2, and the MK 7634 substance showed an excretion rate of 97.4 at 6.06 mg Zkg. 6 is shown. Furthermore, even when this substance was administered at 31.9 mg / kg, the body weight gain was almost the same as that of the non-drug control, confirming that MK7634 is a relatively safe substance. .
- Table 2 Anthelmintic test of roundworm by administration of MK 7634 substance Chicken number Dosage Exclusion rate Gain rate
- the MK7634 substance of the present invention is expected to be used as an anthelmintic agent for parasites in humans and animals or livestock and poultry.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Feed For Specific Animals (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP95937171A EP0794193B1 (en) | 1994-11-24 | 1995-11-22 | Substance mk7634, process for production thereof, and anthelminthic containing said substance |
AU39357/95A AU696583B2 (en) | 1994-11-24 | 1995-11-22 | Substance MK7634, process for production thereof, and anthelminthic containing said substance |
AT95937171T ATE190980T1 (de) | 1994-11-24 | 1995-11-22 | Substanz mk7634, verfahren zu ihrer herstellung und sie enthaltendes anthelminthikum |
DK95937171T DK0794193T3 (da) | 1994-11-24 | 1995-11-22 | Substans MK7634, fremgangsmåde til fremstilling heraf samt anthelmintisk middel indeholdende denne substans |
DE69515903T DE69515903T2 (de) | 1994-11-24 | 1995-11-22 | Substanz mk7634, verfahren zu ihrer herstellung und sie enthaltendes anthelminthikum |
US08/849,301 US6007812A (en) | 1994-11-24 | 1995-11-22 | Compound MK7634, process for production thereof, and anthelmintic containing said substance |
CA002205420A CA2205420C (en) | 1994-11-24 | 1995-11-22 | Substance mk7634, process for production thereof, and anthelminthic containing said substance |
NZ295747A NZ295747A (en) | 1994-11-24 | 1995-11-22 | Fungus derived metabolite |
JP51673896A JP3335177B2 (ja) | 1994-11-24 | 1995-11-22 | Mk7634物質およびその製造法、ならびにmk7634物質を含有する駆虫剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6/290057 | 1994-11-24 | ||
JP29005794 | 1994-11-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996016070A1 true WO1996016070A1 (fr) | 1996-05-30 |
Family
ID=17751235
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1995/002387 WO1996016070A1 (fr) | 1994-11-24 | 1995-11-22 | Substance mk7634, procede de production de ladite substance et anthelmintique la contenant |
Country Status (13)
Country | Link |
---|---|
US (1) | US6007812A (ja) |
EP (1) | EP0794193B1 (ja) |
JP (1) | JP3335177B2 (ja) |
KR (1) | KR100406516B1 (ja) |
CN (1) | CN1067081C (ja) |
AT (1) | ATE190980T1 (ja) |
AU (1) | AU696583B2 (ja) |
DE (1) | DE69515903T2 (ja) |
DK (1) | DK0794193T3 (ja) |
ES (1) | ES2145932T3 (ja) |
NZ (1) | NZ295747A (ja) |
PT (1) | PT794193E (ja) |
WO (1) | WO1996016070A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7001907B2 (en) | 1997-10-07 | 2006-02-21 | Cephaon, Inc. | Peptide-containing α-ketoamide cysteine and serine protease inhibitors |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1434920A (fr) * | 1959-07-31 | 1966-04-15 | Upjohn Co | Procédé d'obtention de la streptozotocine |
DK223690D0 (da) * | 1990-09-17 | 1990-09-17 | Novo Nordisk As | Hidtil ukendte forbindelser |
CA2056222A1 (en) * | 1990-11-28 | 1992-05-29 | Takashi Mikawa | Peptide compound, pharmaceutical composition and feed additive for animal |
-
1995
- 1995-11-22 NZ NZ295747A patent/NZ295747A/en not_active IP Right Cessation
- 1995-11-22 DK DK95937171T patent/DK0794193T3/da active
- 1995-11-22 US US08/849,301 patent/US6007812A/en not_active Expired - Fee Related
- 1995-11-22 AT AT95937171T patent/ATE190980T1/de not_active IP Right Cessation
- 1995-11-22 PT PT95937171T patent/PT794193E/pt unknown
- 1995-11-22 WO PCT/JP1995/002387 patent/WO1996016070A1/ja active IP Right Grant
- 1995-11-22 DE DE69515903T patent/DE69515903T2/de not_active Expired - Lifetime
- 1995-11-22 EP EP95937171A patent/EP0794193B1/en not_active Expired - Lifetime
- 1995-11-22 ES ES95937171T patent/ES2145932T3/es not_active Expired - Lifetime
- 1995-11-22 JP JP51673896A patent/JP3335177B2/ja not_active Expired - Fee Related
- 1995-11-22 KR KR1019970703435A patent/KR100406516B1/ko not_active IP Right Cessation
- 1995-11-22 CN CN95197347A patent/CN1067081C/zh not_active Expired - Fee Related
- 1995-11-22 AU AU39357/95A patent/AU696583B2/en not_active Ceased
Non-Patent Citations (1)
Title |
---|
J01, MB; AHMDL. J., MAHARASHTRA AGRIC. UNIV., 1(1), 1977, pages 37-39. * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7001907B2 (en) | 1997-10-07 | 2006-02-21 | Cephaon, Inc. | Peptide-containing α-ketoamide cysteine and serine protease inhibitors |
Also Published As
Publication number | Publication date |
---|---|
ATE190980T1 (de) | 2000-04-15 |
JP3335177B2 (ja) | 2002-10-15 |
AU696583B2 (en) | 1998-09-17 |
CN1067081C (zh) | 2001-06-13 |
AU3935795A (en) | 1996-06-17 |
EP0794193A4 (en) | 1998-06-10 |
DE69515903T2 (de) | 2000-10-26 |
ES2145932T3 (es) | 2000-07-16 |
KR100406516B1 (ko) | 2004-06-24 |
US6007812A (en) | 1999-12-28 |
NZ295747A (en) | 1998-04-27 |
PT794193E (pt) | 2000-08-31 |
DE69515903D1 (de) | 2000-04-27 |
DK0794193T3 (da) | 2000-12-04 |
EP0794193B1 (en) | 2000-03-22 |
EP0794193A1 (en) | 1997-09-10 |
CN1173180A (zh) | 1998-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2608479B2 (ja) | 環状デプシペプチド物質およびその製造法、ならびにそれを含有する駆虫剤 | |
JPH09505567A (ja) | 多環式駆虫薬、その製造のための方法及び菌株、並びにその用途 | |
CN102731365A (zh) | 猴头菌抑制幽门螺杆菌的生物小分子及其在治疗消化道疾病中的应用 | |
JP2860370B2 (ja) | 抗生物質bu―3608dおよびbu―3608e | |
WO1998056755A1 (fr) | Substances physiologiquement actives tkr2449, leur procede de preparation et micro-organisme | |
JP3335177B2 (ja) | Mk7634物質およびその製造法、ならびにmk7634物質を含有する駆虫剤 | |
JP3521110B2 (ja) | 環状ペプチド化合物及びその製造方法 | |
JP2805564B2 (ja) | 新規物質pf1101b物質及びその製造法 | |
JP2863934B2 (ja) | 抗生物質プラスバシン | |
CA2205420C (en) | Substance mk7634, process for production thereof, and anthelminthic containing said substance | |
JPH08131180A (ja) | サイトカラシンの製造法及びそれらを含有する抗コクシジウム剤 | |
JP3490095B2 (ja) | 抗生物質tkr2648及びその製造方法 | |
KR970002492B1 (ko) | 신규 트리펩티드 유도체 | |
CA1338169C (en) | Compounds wf 2015 a and b, production thereof and use thereof | |
JP3078845B2 (ja) | スピロラキシンおよびスピロラキシンメチルエーテルの製造法 | |
JPH05331172A (ja) | 生物活性プソイロチンaおよびd、アスペルギルス・フミガタスから得られる新規な代謝産物、その調製方法およびその使用 | |
JPH05194571A (ja) | 新規抗生物質nk374186a、nk374186b、nk374186b3及びnk374186c3、その製造法及びその用途 | |
JPH08176157A (ja) | 新規生理活性物質エポスタチン、その製造法およびその用途 | |
EP0488224A2 (en) | Fermentationproduct of a Verticimonosporium strain and feed additivs containing a linear peptide | |
JPH07258263A (ja) | 神経細胞分化促進剤およびその製造法 | |
EP0394868A1 (en) | New antibiotics NK372135, process for the production thereof and use thereof | |
JPH09511902A (ja) | Wf15604物質 | |
JP2003026684A (ja) | Mb7056a物質およびmb7056b物質、その製造法並びにその用途 | |
KR20010035617A (ko) | 5-디메틸오발리신을 함유하는 신생혈관 형성 저해 조성물 및 이를 생산하는 방법 | |
JPH1112296A (ja) | 抗真菌化合物afa0424 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 95197347.9 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA CN JP KR NZ US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 08849301 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 295747 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2205420 Country of ref document: CA Ref document number: 2205420 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019970703435 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995937171 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1995937171 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019970703435 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1995937171 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1019970703435 Country of ref document: KR |